New Weight-Loss Pill (Orforglipron) Expected in the UK by 2026

Orforglipron is a once-daily oral GLP-1 weight-loss medicine developed by Eli Lilly. It was approved in the United States under the brand name Foundayo on 1 April 2026, but it is not currently confirmed as routinely available for weight-management prescribing in the UK.

NICE is assessing orforglipron for managing overweight and obesity in England. Its guidance is currently expected to be published on 18 November 2026, although that date may change. This is not a confirmed UK launch date, and availability would still depend on regulatory authorisation, pricing, supply and commercial arrangements.

The treatment has attracted significant attention because it is taken as a tablet rather than a weekly injection. However, orforglipron is not a tablet version of Mounjaro. It contains a different active ingredient and works in a different way.

Regulatory status last reviewed: 24 July 2026

Orforglipron UK Status at a Glance

What is Orforglipron?

Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist taken as a once-daily tablet. It is designed to support long-term weight management when used alongside a reduced-calorie diet and increased physical activity.

GLP-1 is a naturally occurring hormone involved in:

•       appetite regulation

•       feelings of fullness

•       digestion

•       blood-glucose control

By activating GLP-1 receptors, orforglipron can reduce appetite and energy intake. This may help people eat smaller portions and lose weight over time.

Unlike injectable medicines such as Mounjaro and injectable Wegovy, orforglipron is swallowed as a tablet. The authorised US product can be taken once daily without the strict food and water timing restrictions associated with some oral semaglutide products. Patients should always follow the instructions supplied with the product authorised in their country.

Orforglipron is marketed in the United States as Foundayo. It should not be confused with Mounjaro, which contains tirzepatide.

Clinical Trial Results

The Phase 3 ATTAIN-1 trial evaluated orforglipron in adults with obesity, or overweight with at least one weight-related health condition, who did not have diabetes.

Participants received orforglipron or a placebo alongside diet and physical-activity support for 72 weeks.

How much weight did participants lose?

At the highest studied dose, participants represented by the efficacy estimand lost an average of approximately 12.4% of their starting body weight over 72 weeks.

Results were lower when analysed regardless of whether participants stopped treatment or fully adhered to it. This distinction matters because weight-loss figures can differ depending on how trial results are analysed.

The study concluded that once-daily orforglipron produced significantly greater weight loss than placebo. Its adverse-event profile was broadly consistent with other GLP-1 receptor agonists.

An earlier Phase 2 study reported weight loss of up to 14.7% at 36 weeks in some dose groups. That result should not be directly compared with the Phase 3 figure because the trials differed in design, duration, doses and analytical methods.

What other health measures improved?

Participants receiving orforglipron also experienced improvements in several cardiometabolic measures, including:

•       waist circumference

•       triglycerides

•       non-HDL cholesterol

•       systolic blood pressure

These improvements do not mean that the medicine will be suitable for everyone. Individual results depend on dose, treatment adherence, diet, physical activity, medical history and tolerability.

How Does Orforglipron Compare to Other Options?

Orforglipron's main distinction is that it combines GLP-1 receptor activity with a once-daily tablet format.

However, weight-loss percentages from separate trials should not be treated as direct head-to-head comparisons. Trial populations, doses, study lengths and methods can differ substantially.

For a fuller breakdown of how these treatments compare in practice, see our GP-led comparison of Wegovy, Mounjaro and Ozempic.

A semaglutide tablet for weight management became the first GLP-1 weight-loss tablet approved in the UK in June 2026. This means orforglipron would not be the first oral GLP-1 weight-management medicine available in the UK if it is later authorised.

Orforglipron vs Mounjaro

Mounjaro contains tirzepatide and is administered as a weekly injection. It activates both GIP and GLP-1 receptors.

Orforglipron is a daily tablet and activates GLP-1 receptors.

A head-to-head obesity trial comparing tirzepatide with injectable semaglutide found an average weight reduction of 20.2% with tirzepatide over 72 weeks. This does not prove that every patient will lose more weight with Mounjaro than with orforglipron, but it demonstrates why separate trial percentages should not be described as equivalent.

There has not been a suitable head-to-head trial establishing that orforglipron provides the same average weight loss as Mounjaro.

Orforglipron vs Wegovy

Both medicines activate GLP-1 receptors, but they contain different active ingredients.

Orforglipron contains orforglipron, while Wegovy contains semaglutide. Wegovy is available in injectable form, and an oral semaglutide version for weight management was approved in the UK in June 2026.

The practical differences may include:

•       active ingredient

•       tablet or injection format

•       food and water instructions

•       dosing schedule

•       side-effect profile

•       treatment eligibility

•       cost and availability

Orforglipron vs Rybelsus

Rybelsus and orforglipron are both oral GLP-1 medicines, but they contain different active ingredients and have different authorised uses.

Rybelsus contains semaglutide and is used primarily for type 2 diabetes. Traditional oral semaglutide formulations have specific fasting, water and timing requirements.

The authorised US version of orforglipron can be taken without the same food and water restrictions.

Orforglipron vs Orlistat and Mysimba

Orlistat and Mysimba are existing oral weight-management treatments, but they do not work through GLP-1 receptors.

Orlistat reduces the amount of dietary fat absorbed by the body. Mysimba influences appetite and reward pathways through the combined action of naltrexone and bupropion.

Orforglipron produced clinically meaningful weight loss in its Phase 3 trial, but the most suitable medicine depends on individual health, contraindications, previous treatment response and patient preference.

Is Orforglipron the Mounjaro Pill?

No. Orforglipron is not a pill form of Mounjaro.

Mounjaro contains tirzepatide, while orforglipron contains a different active ingredient.

Mounjaro:

•       is administered as a weekly injection

•       acts on GIP and GLP-1 receptors

•       contains tirzepatide

Orforglipron:

•       is taken as a daily tablet

•       acts on GLP-1 receptors

•       contains orforglipron

People frequently describe orforglipron as the "Mounjaro pill" because both medicines were developed by Eli Lilly and are associated with weight management.

However, they are separate medicines and are not interchangeable.

Is Eli Lilly developing Mounjaro tablets?

There is no confirmed UK release date for a tablet containing tirzepatide, the active ingredient in Mounjaro.

Orforglipron is Eli Lilly's oral GLP-1 medicine. It is not oral tirzepatide and should not be marketed or described as a Mounjaro tablet.

When Will Orforglipron Be Available in the UK?

There is no confirmed UK release date for orforglipron.

The medicine received FDA approval in the United States under the Foundayo brand on 1 April 2026. US approval does not automatically authorise a medicine for sale or prescribing in the UK.

NICE is developing guidance on the clinical and cost effectiveness of orforglipron for managing obesity or overweight with at least one related health condition.

Its appraisal is currently expected to be published on 18 November 2026.

A NICE appraisal is not the same as:

•       MHRA marketing authorisation

•       a confirmed commercial launch

•       immediate private availability

•       guaranteed NHS access

Potential UK availability may depend on:

•       regulatory authorisation

•       the manufacturer's commercial plans

•       medicine supply

•       private prescribing arrangements

•       NICE guidance

•       NHS commissioning decisions

This sits within a wider pattern of stricter weight-loss jab regulation across the UK.

Can I get orforglipron privately in the UK now?

Orforglipron is not currently confirmed as routinely available for private weight-management prescribing in the UK.

Patients should be cautious of websites claiming to sell, import, pre-order or provide orforglipron without an appropriate UK prescribing and dispensing pathway.

Prescription weight-loss medicines should only be supplied following a proper clinical assessment and dispensed through a registered pharmacy.

The MHRA advises that GLP-1 medicines should only be used for licensed medical purposes and should not be obtained for purely cosmetic weight loss or through unsafe, unregulated channels.

Will orforglipron be available on the NHS?

NHS availability has not been confirmed.

Any future NHS access could depend on:

•       UK marketing authorisation

•       a positive NICE recommendation

•       agreed eligibility criteria

•       cost effectiveness

•       commissioning arrangements

•       treatment capacity

•       available supply

The expected NICE publication date should not be interpreted as a guaranteed NHS rollout date.

How Much Will Orforglipron Cost in the UK?

A confirmed UK price for orforglipron has not been announced.

It is therefore not currently possible to state accurately:

•       its monthly private cost

•       the cost of each dose

•       whether it will be cheaper than Mounjaro

•       whether it will be funded by the NHS

•       whether consultation and monitoring fees will be included

Any future private cost could depend on:

•       the authorised dose

•       manufacturer and wholesaler pricing

•       pharmacy dispensing costs

•       consultation charges

•       clinical monitoring fees

•       treatment supply

•       the prescribing provider

NHS pricing and availability would be considered separately and may depend on a future NICE cost-effectiveness recommendation.

Will orforglipron be cheaper than Mounjaro?

That is not yet known.

A tablet may be simpler to manufacture, transport or store than an injectable pen, but this does not guarantee a lower private retail price. This is worth bearing in mind given recent Mounjaro price changes in the UK market.

Any credible comparison should wait until:

•       an official UK price is published

•       authorised doses are confirmed

•       private prescribing arrangements are available

•       pharmacy and provider fees are known

Claims that orforglipron will cost a specific amount per month in the UK are currently speculative unless supported by an official announcement.

Who Could Benefit?

UK eligibility criteria for orforglipron have not yet been confirmed.

They may depend on the wording of any future UK marketing authorisation and NICE guidance.

In the United States, Foundayo is authorised alongside a reduced-calorie diet and increased physical activity for adults with:

•       obesity

•       overweight and at least one weight-related medical condition

The FDA indication covers long-term weight reduction in eligible adults.

Weight-related conditions may include:

•       type 2 diabetes

•       high blood pressure

•       abnormal cholesterol levels

•       cardiovascular disease

•       obstructive sleep apnea

Any future UK criteria may differ.

If authorised in the UK, the tablet format could be particularly useful for some people who:

•       prefer tablets to injections

•       are uncomfortable using needles

•       find injectable pens difficult to transport

•       have difficulty administering injections

•       are clinically suitable for a GLP-1 medicine

However, preference for a tablet would not determine eligibility by itself.

A qualified prescriber would need to assess:

•       current weight and BMI

•       weight-related health risks

•       medical history

•       current medicines

•       previous treatment response

•       possible contraindications

•       pregnancy or pregnancy plans

•       gastrointestinal symptoms

•       pancreatitis and gallbladder history

•       whether another treatment is more suitable

Side Effects and Safety

Orforglipron can cause side effects and will not be suitable for everyone.

In clinical trials, the most frequently reported adverse effects involved the digestive system.

Common effects included:

•       nausea

•       vomiting

•       diarrhoea

•       constipation

•       abdominal pain or discomfort

•       indigestion

•       reduced appetite

Gastrointestinal effects were particularly common during dose escalation. In the earlier Phase 2 trial, some participants stopped treatment because of these effects.

Some symptoms may improve as the body adjusts, but persistent, severe or worsening symptoms should not automatically be assumed to be temporary.

The current US prescribing information includes warnings and precautions relating to potentially serious complications, including:

•       acute pancreatitis

•       severe gastrointestinal reactions

•       dehydration

•       kidney injury related to fluid loss

•       gallbladder problems

•       hypoglycaemia when used with certain diabetes medicines

•       serious allergic reactions

•       a boxed warning regarding thyroid C-cell tumours based on animal findings

Patients should follow the safety information provided with the authorised medicine and discuss individual risks with a qualified clinician.

The MHRA has also strengthened warnings concerning acute pancreatitis for GLP-1 receptor agonists and dual GIP/GLP-1 medicines used in the UK.

Seek urgent medical advice if you experience:

•       severe or persistent abdominal pain

•       abdominal pain that spreads to the back

•       repeated vomiting

•       inability to keep fluids down

•       symptoms of significant dehydration

•       swelling of the face, lips, tongue or throat

•       difficulty breathing

•       symptoms of severe low blood sugar when using insulin or certain diabetes medicines

Treatment should only be started after an individual clinical assessment.

Can You Buy Orforglipron in the UK?

Orforglipron is not currently confirmed as routinely available to buy or obtain through a private UK prescription.

Patients should not attempt to purchase it from:

•       unofficial online sellers

•       social-media accounts

•       overseas suppliers without a lawful pathway

•       websites offering unverified pre-orders

•       sellers that do not require a consultation

•       suppliers that cannot identify the dispensing pharmacy

A legitimate prescription weight-loss service should involve:

•       an assessment by a suitably qualified prescriber

•       confirmation that the treatment is clinically appropriate

•       a valid prescription

•       dispensing through a registered pharmacy

•       authentic, regulated medication

•       appropriate monitoring and follow-up

Unregulated products may be:

•       counterfeit

•       contaminated

•       incorrectly dosed

•       stored improperly

•       supplied without safety information

•       unsuitable for the person taking them

The MHRA has previously issued warnings after fake weight-loss injections were sold in the UK, underlining why medicines should only be sourced through a registered pharmacy.

Patients seeking treatment now can discuss weight-management medicines that are currently authorised in the UK with a qualified clinician.

The Future of Oral Weight-Loss Treatment

Orforglipron forms part of a broader shift towards oral treatments for obesity and overweight.

Until recently, the most prominent GLP-1 weight-management medicines were administered by injection. The UK approval of an oral semaglutide weight-management tablet in June 2026 demonstrated that oral GLP-1 treatment is now becoming a practical prescribing category rather than a purely investigational concept.

Future oral treatments may reduce barriers for people who:

•       dislike injections

•       have difficulty using pen devices

•       travel frequently

•       prefer tablets

•       experience storage or transport challenges

However, oral administration does not automatically make a medicine:

•       safer

•       more effective

•       cheaper

•       suitable for more people

•       free from monitoring requirements

The most appropriate treatment will continue to depend on clinical evidence, individual risk, treatment response, availability and patient preference.

Key Takeaway

Orforglipron is a once-daily oral GLP-1 weight-management medicine marketed in the United States as Foundayo.

It received FDA approval on 1 April 2026, but an exact UK release date and UK price have not been confirmed. NICE is developing guidance for England, with publication currently expected in November 2026.

Orforglipron is not a tablet version of Mounjaro. Mounjaro contains tirzepatide and acts on both GIP and GLP-1 receptors, while orforglipron is a separate oral GLP-1 receptor agonist.

In the Phase 3 ATTAIN-1 trial, participants represented by the efficacy estimand who received the highest dose lost an average of approximately 12.4% of their starting weight over 72 weeks. Individual results and treatment suitability vary.

At Private Medical Clinic, we monitor regulatory and clinical developments in weight-management treatment.

Patients interested in treatment now can arrange a weight loss assessment to discuss currently authorised options, including whether medicines such as Mounjaro or Wegovy may be clinically appropriate.

Orforglipron should not be purchased from unregulated sellers or promoted as available through a routine UK prescribing pathway unless the necessary authorisation and supply arrangements are in place.

Frequently Asked Questions About Orforglipron

‍